The detection rates and tumor clinical/pathological stages of whole-body FDG-PET cancer screening

Annals of Nuclear Medicine

Volumn 21, Issue 1, 2007, Pages 65-72

  Ono, Ken ^a,b   Ochiai, Reiji ^a   Yoshida, Tsuyoshi ^a   Kitagawa, Mami ^a   Omagari, Junichi ^a   Kobayashi, Hisashi ^a   Yamashita, Yasuyuki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SHIN KOGA HOSPITAL   (Japan)

Author keywords

Cancer screening; Detection rate; FDG PET; Stage

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SCREENING; CANCER STAGING; COLON CANCER; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC IMAGING; ECHOGRAPHY; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; GALLBLADDER CANCER; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOLOGICAL TECHNIQUE; KIDNEY CANCER; LARYNX CANCER; LIVER CANCER; LUNG CANCER; MALE; OCCULT BLOOD; PANCREAS CANCER; PHARYNX CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUESTIONNAIRE; RETROPERITONEAL CANCER; STOMACH CANCER; THYROID CANCER; WHOLE BODY CT;

EID: 33847160801     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03034001     Document Type: Article

References (35)

1. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-1674.
2. Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32: 1508-1512.
3. Price P, Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? Eur J Cancer 1995; 31A: 1924-1927.
4. Okada J, Oonishi H, Yoshikawa K, Itami J, Uno K, Imaseki K, et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994; 8: 187-191.
5. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 1997; 79: 695-699.
6. 18F-D-glucose. Cancer 1998; 82: 2227-2234.
7. Guerrero TM, Hoffman EJ, Dahlbom M, Cutler PD, Hawkins RA, Phelps ME. Characterization of a whole body imaging technique for PET. IEEE Trans Nucl Sci 1990; 37 (2): 676-680.
8. Conti PS, Lilien DJ, Hawley K, Keppler J, Grafton ST, Bading JR. PET and 18-[F] FDG in oncology: a clinical update. Nucl Med Biol 1996; 23: 717-735.
9. Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer lymphoma and melanoma. J Nucl Med 1999; 40: 591-603.
10. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 1999; 35: 1076-1082.
11. 18F-fluorodeoxyglucose positron-emission tomography. The Lancet 1997; 350: 1819.
12. Chen YK, Ding HJY, Su CT, Shen YY, Chen LK, Liao AC, et al. Application of PET and PET/CT imaging for Cancer Screening. Anticancer Res 2004; 24: 4103-4108.
13. 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening. Neoplasma 2003; 50 (3): 217-221.
14. Ide M. Cancer screening with FDG-PET. Jpn J Clin Radiol 2004; 49: 835-840.
15. 18F- fluorodeoxyglucose positron emission tomography in cancer screening - A preliminary report. Oncology Reports 2001; 8: 1145-1148.
16. Yasuda S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Takahashi W, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer 2000; 83 (12): 1607-1611.
17. Jinnouchi S. Could FDG-PET change the conventional scheme of cancer screening? Jpn J Clin Radiol 2004; 49: 855-863.
18. Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996; 37: 441-446.
19. Sobin LH, Wittekind CH, eds. TNM Classification of Malignant Tumors, 5th ed. New York; John Wiley & Sons, Inc., 1997.
20. Japan Cancer Society. The Statistics of Cancer Screening 2003. Tokyo; Japan Cancer Society, 2003.
21. Japanese Society of Gastroenterological Mass Survey. Annual report of gastroenterological mass survey in Japan 2002. Tokyo; Japanese Society of Gastroenterological Mass Survey, 2002.
22. Uno K, Woo J, Suzuki T, Suzuki H, Kosaka N, Matsuo Y, et al. What are the problems of cancer screening using FDG-PET? Jpn J Clin Radiol 2004; 49: 841-846.
23. Chung WY, Chang HS, Kim EK, Park CS. Ultrasonographic mass screening for thyroid carcinoma: a study in women scheduled to undergo a breast examination. Surgery Today 2001; 31: 763-767.
24. Siironen P, Louhimo J, Nordling S, Ristimäki A, Mäenpä ä H, Haapiainen R, et al. Prognostic Factors in Papillary Thyroid Cancer: An Evaluation of 601 Consecutive Patients. Tumor Biology 2005; 26: 57-64.
25. Sobue T, Moriyama N, Kaneko M, Kusumoto M, Kobayashi T, Tsuchiya R, et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol 2002; 20 (4): 911-920.
26. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer 2004; 45 (1): 19-27.
27. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med 2003; 30 (2): 288-295.
28. Hofer C, Kubler H, Hartung R, Breul J, Avril N. Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol 2001; 40 (5): 481-487.
29. Merminod T, Zulian GB. Multiple malignant tumours in the elderly. Crit Rev Oncol Hematol 2002; 43 (3): 227-230.
30. Nishiyama Y, Yamamoto Y, Yokoe K, Miyabe K, Ogawa T, Toyama Y, et al. FDG PET as a procedure for detecting simultaneous tumours in head and neck cancer patients. Nucl Med Commun 2005; 26: 239-244.
31. Ishimori T, Patel PV, Wahl RL. Detection of Unexpected Additional Primary Malignancies with PET/CT. J Nucl Med 2005; 46: 752-757.
32. Di Martino E, Nowak B, Hassan HA, Hausmann R, Adam G, Buell U, et al. Diagnosis and staging of head and neck cancer. Arch Otolaryngol Head Neck Surg 2000; 126: 1457-1461.
33. Robert G, Milne R. A Delphi study to establish national cost-effectiveness research priorities for positron emission tomography. Eur J Radiol 1999; 30: 54-60.
34. Vade A, Demos TC, Olson MC, Subbaiah P, Turbin RC, Vickery K, et al. Evaluation of image quality using 1:1 pitch and 1.5:1 pitch helical CT in children: a comparative study. Pediatr Radiol 1996; 26: 891-893.
35. Yasuda S, Ide M. PET and cancer screening. Ann Nucl Med 2005; 19 (3): 167-177.